Navigation Links
Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
Date:5/29/2008

WOODCLIFF LAKE, N.J., May 29 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that its development partner, Alfacell Corporation (Nasdaq: ACEL) reported that the preliminary statistical analysis of data from its confirmatory Phase IIIb clinical trial of its lead compound, ONCONASE (ranpirnase), did not meet statistical significance for the primary endpoint of survival in unresectable malignant mesothelioma (UMM). However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen.

The preliminary results are based on 320 evaluable events that occurred in the clinical trial out of a total of 428 patients randomized. The trial was designed to show a statistically significant improvement in overall survival (p < 0.048) for UMM patients who were treated with a combination of ONCONASE plus doxorubicin as compared to patients who were treated with doxorubicin as a single agent. The analysis of the data did not show a statistically significant improvement for evaluable patients receiving ONCONASE plus doxorubicin (unadjusted log rank p=0.80). The median survival time (MST) for evaluable patients who received ONCONASE plus doxorubicin was 11.1 months as compared to 10.7 months for patients who received doxorubicin as a single agent.

Statistically significant results were achieved in evaluable UMM patients who failed a prior chemotherapy
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
2. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
3. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
6. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
7. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SAN DIEGO , Aug. 29, 2014 /PRNewswire/ ... an emerging biopharmaceutical company, announced today that Santosh ... will be leaving the Company, for personal reasons, ... the Chief Medical Officer of Aires Pharmaceuticals, which ... Vetticaden,s former responsibilities as the Company,s interim Chief ...
(Date:8/29/2014)... 2014 Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... Stanley Global Healthcare Conference on Wednesday, September 10. ... Executive Officer, will provide an update on the company, ... Pacific Daylight Time).   A webcast of ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... and WALTHAM, Mass., May 25, 2011 Interleukin Genetics, Inc. ... USP Hospitales now offers the innovative Heart Health Genetic ... Hospitales, the flagship hospital in Madrid, and will soon ... identifies single nucleotide variations in two Interleukin-1 (IL-1) genes ...
... May 25, 2011 Cambridge Temperature Concepts (CTC), ... has been awarded an I Award by the Wireless-Life ... to solving healthcare challenges . DuoFertility uses wireless technology to ... a baby the best possible chance of conceiving naturally. News ...
Cached Medicine Technology:USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 2USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 3USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 4Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility 2Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility 3Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility 4
(Date:8/29/2014)... Angeles, CA (PRWEB) August 29, 2014 ... inspired others who talked about introducing these cutting ... experience as chairman of the FUE Research Committee has ... studies that redefine what is possible with modern technology. ... of a variety of FUE devices that facilitate extraction ...
(Date:8/29/2014)... 2014 According to a CNN article, ... (8/25), a new study found that those states ... seen a significant decrease in the number of painkiller ... ten year period, and comparing various states with and ... that there was about a 25% decrease in painkiller ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 As reported by ... Monitoring For Drug Abuse Trends , Outbreaks (8/20), the National ... attempt to monitor drug abuse trends by turning to social ... drug abuse trends, it is also working with the University ... National Drug Early Warning System, which will be funded by ...
(Date:8/29/2014)... An article entitled How Genes, Gender and ... explains how genes, gender and the environment that an individual ... drugs. Researchers at Indiana University are taking another look at ... and are applying this factor to what is known about ... family and community ties can help to reduce a man’s ...
(Date:8/29/2014)... 29, 2014 Healthpointe is proud to ... Dr. Rodas will be practicing out of Healthpointe’s newest ... member of Healthpointe’s orthopedic team, Dr. Rodas ... and board-certified in occupational medicine. , Among Dr. ... Medical Director of Raytheon, the world-class defense and aerospace ...
Breaking Medicine News(10 mins):Health News:Parsa Mohebi M.D., Beverly Hills Hair Restoration Surgeon Gives Inspiring Lecture on Groundbreaking Techniques in Follicular Unit Extraction 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 3Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Substance Abuse Likelihood Affected by Environment, Gender and Genes 2Health News:Substance Abuse Likelihood Affected by Environment, Gender and Genes 3Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2
... in necessary prescriptions, study finds , , TUESDAY, Feb. 3 ... "doughnut hole" in the Medicare Part D drug plan ... with an employer-based plan, a new study finds. , ... costs from hospitalizations and doctor visits resulting from this ...
... Ala. Exposure to second-hand smoke and alcohol significantly ... at the University of Alabama at Birmingham (UAB). , ... and alcohol are worse for health as a combination, ... an associate professor in the UAB Department of Environmental ...
... Group, Inc.,(NYSE Alternext US: QGP) ( www.QuantumMD.com ) announced ... debut at the 2009 Pri-Med,South Conference and Expo alongside ... Quantum believes PWeR is the next generation in healthcare ... Obama is calling for within,the industry. Pete Martinez, ...
... A thesis from the Sahlgrenska Academy, University of Gothenburg, ... suicide attempt are five times more likely to attempt ... nightmares. , The study included 165 patients aged ... psychiatric departments following a suicide attempt in Sweden. Psychiatric ...
... Feb. 3 Physicians have been raving about the ... 2008 survey of U.S. VASER Lipo physicians, 95% of ... physician or facility. The VASER Lipo System ... contouring applications from precise sculpting to significant fat removal."Hundreds ...
... improve writing skills for those with aphasia with the aid ... doctoral thesis from the Sahlgrenska Academy at the University of ... use spoken language, and the ability to read and write. ... writing aids in the study on which speech and language ...
Cached Medicine News:Health News:Medicare Drug Plan 'Doughnut Hole' Could Impact Seniors' Health 2Health News:Tobacco smoke and alcohol harm liver worse as combo 2Health News:PWeR(TM) Introduced at Regional Healthcare Conference 2Health News:PWeR(TM) Introduced at Regional Healthcare Conference 3Health News:PWeR(TM) Introduced at Regional Healthcare Conference 4Health News:Nightmares increase risk of further suicide attempts 2Health News:THE RESULTS ARE IN! VASER(R) Lipo Receives 95% Approval Rating by Physician Users 2Health News:Computerized writing aids make writing easier for persons with aphasia 2
... segment surgical procedures. For dissection of vitreoretinal ... luer lock tubing set is attached to ... - .02in (.50mm); OD - .06in (1.5mm) ... viscoelastic fluids. 30G (.30mm) tip, flattened. Angled ...
Product designed specifically for posteror segment surgical procedures. Facilitates posterior segment infusion. Flexible tubing 10in (25cm)....
For surgical treatment, repair and irrigation of the nasolacrimal system. Silicone tubing. Length 14in (35cm) ID: .012in (.30mm) OD: .025in (.60mm)...
...
Medicine Products: